Gene Expression Profiles Differentiating Between Breast Cancers Clinically Responsive or Resistant to Letrozole

Endocrine agents, such as letrozole, are established in the treatment of hormone-dependent breast cancer. However, response rates are only 50% to 70% in the neoadjuvant setting and lower in advanced disease. Thus there is a need to identify novel markers predicting for response and to understand mol...

Ausführliche Beschreibung